Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2026-06-02 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于第二期员工持股计划出售完毕暨提前终止的公告
Transaction in Own Shares Classification · 85% confidence The document is an official corporate announcement by Shenzhen BGI Genomics Co., Ltd. regarding the completion of share sales held under its second employee stock ownership plan and the plan’s early termination. This constitutes a report on the company’s (through its employee plan) sale of its own shares. It does not contain financial statements or voting results, nor is it an earnings release, M&A notice, or board change. Therefore, it fits the definition of “Transaction in Own Shares” (code POS).
2026-06-02 Chinese
关于收购重庆新一产生命科技有限公司100%股权暨关联交易的进展公告
M&A Activity Classification · 70% confidence The document is a public progress announcement (“进展公告”) by Shenzhen BGI Co., Ltd. concerning its related-party acquisition of 100% equity in Chongqing Xinyichan Life Science Technology Co., Ltd. It details board approvals, registration changes, and updated shareholding structure, all in relation to an acquisition. This falls under M&A activity disclosures rather than financial statements, earnings releases, or share issues. Therefore, it best matches the M&A Activity category (TAR).
2026-05-29 Chinese
关于第二期员工持股计划首次授予部分第三个锁定期届满暨解锁条件未成就的公告
Regulatory Filings Classification · 85% confidence The document is a formal disclosure from Shenzhen BGI Genomics regarding the expiry of a lock-up period under its second employee share ownership plan and the fact that unlocking conditions were not met. It contains no financial statements or results, is not a call transcript or earnings release, and does not announce board changes, dividends, or M&A. It is a compliance/regulatory announcement under Shenzhen Stock Exchange rules and thus falls under the fallback “Regulatory Filings” category (RNS).
2026-05-29 Chinese
关于公司及子公司涉及诉讼的公告
Legal Proceedings Report Classification · 92% confidence The document is a formal announcement by Shenzhen BGI Genomics Co., Ltd. disclosing details of a significant legal proceeding (a lawsuit filed against the company and its subsidiaries) including case background, parties, claims, potential financial impact, and next steps. It contains no financial statements, earnings data, or management changes and is clearly a litigation update. This aligns with the “Legal Proceedings Report (LTR)” category.
2026-05-21 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二五年年度股东会之法律意见书
Regulatory Filings Classification · 72% confidence The document is a legal opinion letter issued by Grandall Law Firm regarding the convening, procedures, attendance and voting results of Shenzhen BGI’s 2025 Annual General Meeting. It is not the Annual Report itself, nor a notice soliciting proxies, or a presentation deck. Instead it is a lawyer’s attestation of compliance and procedural legality, fitting the description of an officer certification/compliance document. Under the Certification Rule and fallback guidance, it should be classified as a general regulatory filing (RNS).
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is titled “2025年年度股东会决议公告” and details the attendance, voting procedures, and precise vote counts and percentages for each resolution at the company’s Annual General Meeting. It publishes the official results of shareholder votes at the AGM, which matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-05-20 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.